Incyte Corporation (INCY) Stock
INCY Key Statistics
About Incyte Corporation
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
CEO: William J. Meury. Company website
INCY — Frequently Asked Questions
What is the INCY stock price today?
Incyte Corporation (INCY) trades at $125.31, down 1.81% on the day, as of Sep 20, 2026 15:00 UTC.
What is Incyte Corporation's market cap?
Incyte Corporation has a market capitalisation of $25.40B, calculated from the live INCY share price and shares outstanding.
What is the P/E ratio of INCY?
INCY trades at a trailing P/E of 15.96, from earnings per share of $7.85 over the last twelve months.
How much revenue does Incyte Corporation make?
Incyte Corporation generated revenue of $5.82B over the trailing twelve months, which puts the stock at 4.36 times sales.
What is the 52-week range for INCY?
INCY has traded between $81.09 and $132.60 over the past 52 weeks, and the last price is 5.5% below that high.
Is Incyte Corporation profitable?
Yes. Incyte Corporation keeps 27.71% of revenue as net income over the trailing twelve months.
What is the analyst price target for INCY?
Wall Street analysts rate INCY Buy, with an average price target of $130.07, 3.8% above the current price.
What sector is Incyte Corporation in?
Incyte Corporation is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Incyte Corporation?
William J. Meury is the chief executive of Incyte Corporation, which employs 2,844 people.
Where can I track INCY in real time?
QFI Terminal shows INCY with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See INCY live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open INCY in Terminal See plans